Private Advisor Group LLC Has $2.56 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Private Advisor Group LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 8.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 6,956 shares of the life sciences company’s stock after acquiring an additional 559 shares during the period. Private Advisor Group LLC’s holdings in Illumina were worth $2,561,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ILMN. Next Capital Management LLC acquired a new stake in Illumina in the second quarter valued at approximately $25,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Illumina in the second quarter valued at approximately $37,000. Trustcore Financial Services LLC acquired a new stake in Illumina in the second quarter valued at approximately $44,000. Focused Wealth Management Inc grew its stake in Illumina by 1,462.5% in the second quarter. Focused Wealth Management Inc now owns 125 shares of the life sciences company’s stock valued at $46,000 after acquiring an additional 117 shares during the period. Finally, Coastal Capital Group Inc. acquired a new stake in Illumina in the second quarter valued at approximately $49,000. 90.90% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $358.15, for a total value of $1,181,895.00. Following the completion of the transaction, the director now directly owns 275,916 shares in the company, valued at approximately $98,819,315.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $371.29, for a total value of $46,039.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,198 shares of company stock worth $17,285,970. Corporate insiders own 0.38% of the company’s stock.

Shares of NASDAQ:ILMN traded up $2.27 during mid-day trading on Friday, hitting $307.47. 22,808 shares of the company traded hands, compared to its average volume of 1,062,303. The stock has a market cap of $43.85 billion, a P/E ratio of 53.80, a P/E/G ratio of 2.78 and a beta of 1.09. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76. The stock has a 50-day moving average price of $287.61 and a two-hundred day moving average price of $313.61.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $838.00 million for the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. Illumina’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the company posted $1.43 earnings per share. As a group, analysts expect that Illumina, Inc. will post 6.04 earnings per share for the current year.

A number of equities research analysts have commented on the company. Deutsche Bank reduced their price objective on Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a research note on Friday, July 12th. Canaccord Genuity cut Illumina from a “buy” rating to a “hold” rating and reduced their price objective for the company from $330.00 to $300.00 in a research note on Tuesday, July 30th. Argus reduced their price objective on Illumina to $340.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Bank of America cut Illumina from a “buy” rating to an “underperform” rating and set a $310.00 target price on the stock. in a research report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $330.92.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: Return on Investment (ROI)

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit